1
|
Zancan M, Galdi F, Di Tonno F, Mazzariol C, Orlando C, Malentacchi F, Agostini M, Maran M, Del Bianco P, Fabricio AS, Murer B, Pianon C, Gion M. Evaluation of Cell-free DNA in Urine as a Marker for Bladder Cancer Diagnosis. Int J Biol Markers 2018; 24:147-55. [DOI: 10.1177/172460080902400304] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The diagnosis and follow-up of bladder cancer are mainly based on cystoscopy, an invasive method which could be negative in case of flat malignancies such as carcinoma in situ. Other noninvasive diagnostic methods have not yet given satisfactory results. There is a need for a reliable yet noninvasive method for the detection of bladder cancer. Our aim was to investigate whether cell-free DNA quantified in urine (ucf-DNA) could be a useful marker for the diagnosis of bladder cancer. A standard urine test was performed in 150 naturally voided morning urine samples that were processed to obtain a quantitative evaluation of ucf-DNA. Leukocyturia and/or bacteriuria were found in 18 subjects, who were excluded from the study. Statistical analysis was performed on 45 bladder cancer patients and 87 healthy subjects. Ucf-DNA was extracted from urine samples by a spin column-based method and quantified using four different methods: GeneQuant Pro (Amersham Biosciences, Pittsburg, PA, USA), Quant-iT™ DNA high-sensitivity assay kit (Invitrogen, Carlsbad, CA, USA), Real-Time PCR (Applied Biosystems, Foster City, CA, USA), and NanoDrop 1000 (NanoDrop Technologies, Houston, TX, USA). Median free DNA quantification did not differ statistically between bladder cancer patients and healthy subjects. A receiver-operating characteristic (ROC) curve was developed to evaluate the diagnostic performance of ucf-DNA quantification for each method. The area under the ROC curve was 0.578 for GeneQuant Pro, 0.573 for the Quant-iT™ DNA high-sensitivity assay kit, 0.507 for Real-Time PCR, and 0.551 for NanoDrop 1000, which indicated that ucf-DNA quantification by these methods is not able to discriminate between the presence and absence of bladder cancer. No association was found between ucf-DNA quantification and tumor size or tumor focality. In conclusion, ucf-DNA isolated by a spin column-based method and quantified by GeneQuant Pro, Quant-iT™ DNA high-sensitivity assay kit, Real-Time PCR or NanoDrop 1000 does not seem to be a reliable marker for the diagnosis of bladder cancer.
Collapse
Affiliation(s)
- Matelda Zancan
- ABO Association, Center for the Study of Biological Markers of Malignancy, AULSS 12, Venice
| | - Francesca Galdi
- ABO Association, Center for the Study of Biological Markers of Malignancy, AULSS 12, Venice
| | - Fulvio Di Tonno
- Unit of Urology, dell'Angelo Hospital, AULSS 12, Mestre-Venice
| | | | - Claudio Orlando
- Clinical Biochemistry and Endocrinology Units, Department of Clinical Physiopathology, University of Florence, Florence
| | - Francesca Malentacchi
- Clinical Biochemistry and Endocrinology Units, Department of Clinical Physiopathology, University of Florence, Florence
| | - Marco Agostini
- Second Division of Surgery, Department of Surgery and Oncology, University of Padua, Padua
| | - Michela Maran
- Unit of Pathology, dell'Angelo Hospital, AULSS 12, Mestre-Venice
| | | | - Aline S.C. Fabricio
- ABO Association, Center for the Study of Biological Markers of Malignancy, AULSS 12, Venice
| | | | - Carlo Pianon
- Unit of Urology, dell'Angelo Hospital, AULSS 12, Mestre-Venice
| | - Massimo Gion
- Center for the Study of Biological Markers of Malignancy, AULSS 12, Venice - Italy
| |
Collapse
|
2
|
Casadio V, Bravaccini S, Gunelli R, Nanni O, Zoli W, Amadori D, Calistri D, Silvestrini R. Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients. Int J Biol Markers 2018; 24:253-7. [DOI: 10.1177/172460080902400406] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Telomerase activity assessment in voided urine is an important noninvasive tool for bladder cancer diagnosis. In a previous case-control study we verified that this method can detect tumor cells in urine with high sensitivity and specificity, but few data are still available on its accuracy to detect tumors in patients with symptomatic urinary tract diseases. Following recently published guidelines on bladder cancer, we aimed to define the diagnostic accuracy of urine telomerase levels in symptomatic patients. Telomerase activity, expressed in arbitrary enzymatic units (AEUs), was evaluated in urine collected from 515 patients: 197 with urinary tract symptoms and 318 with a first diagnosis of bladder cancer. Telomerase repeat amplification protocol (TRAP) sensitivity ranged from 93% to 61% and specificity varied from 42% to 88% at the different AEU cutoff values. At the cutoff of 50, the sensitivity was 87% (95% CI 83–91), the specificity was 70% (95% CI 63–75), and the overall accuracy, in terms of true positives and true negatives, was 80%. Sensitivity did not vary in relation to tumor grade or stage at diagnosis, or to patient age. Our results indicate that urine telomerase activity is a good marker for the early diagnosis of bladder tumors in symptomatic patients, a subset which represents an “at-risk” population requiring close surveillance.
Collapse
Affiliation(s)
- Valentina Casadio
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (Forlì-Cesena)
| | - Sara Bravaccini
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (Forlì-Cesena)
| | - Roberta Gunelli
- Department of Urology, Morgagni-Pierantoni Hospital, Forlì - Italy
| | - Oriana Nanni
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (Forlì-Cesena)
| | - Wainer Zoli
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (Forlì-Cesena)
| | - Dino Amadori
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (Forlì-Cesena)
| | - Daniele Calistri
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (Forlì-Cesena)
- These Auhors contributed equally to the work
| | - Rosella Silvestrini
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (Forlì-Cesena)
- These Auhors contributed equally to the work
| |
Collapse
|
3
|
Minami S, Nagashio R, Ueda J, Matsumoto K, Goshima N, Hattori M, Hachimura K, Iwamura M, Sato Y. Detection of tumor-associated antigens in culture supernatants using autoantibodies in sera from patients with bladder cancer. Biomed Res 2014; 35:25-35. [PMID: 24573199 DOI: 10.2220/biomedres.35.25] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Secreted proteins play essential roles in the process of tumorigenesis, and the analysis of tumor-secreted proteins has been suggested as a promising strategy for identifying cancer biomarkers. In this study, we performed proteomic analysis to identify proteins secreted from bladder cancer cell lines that are recognized by autoantibodies in sera from patients with bladder cancer. In addition,autoantibodies against the identified proteins were validated using a dot-blot array with sera from patients with bladder cancer and normal controls. As the results, we detected twenty-five and thirty-two immunoreactive spots in sera from patients with high- and low-grade bladder cancer, respectively.In addition, validation analysis revealed that serum IgG levels of anti-calreticulin and matrix metalloproteinase-2 (MMP2) autoantibodies were significantly higher in bladder cancer patients than in normal controls (both P < 0.05). Furthermore, the serum IgG level of anti-MMP2 autoantibody was significantly higher in patients with high- compared to low-grade bladder cancer(P < 0.05). On multivariate analysis, the serum IgG level of anti-MMP2 autoantibody was an independent predictor of cancer-specific survival (P < 0.05). Based on these findings, serum IgG levels of anti-calreticulin and MMP2 autoantibodies may be novel biomarker candidates for bladder cancer and its clinical outcome.
Collapse
Affiliation(s)
- Sho Minami
- Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Kitasato1-15-1,Minami-ku, Sagamihara-shi, Kanagawa 252-0373, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Ho CCK, Tan WP, Pathmanathan R, Tan WK, Tan HM. Fluorescence-in-situ-hybridization in the surveillance of urothelial cancers: can use of cystoscopy or ureteroscopy be deferred? Asian Pac J Cancer Prev 2014; 14:4057-9. [PMID: 23991952 DOI: 10.7314/apjcp.2013.14.7.4057] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Fluorescence in situ hybridization (FISH) testing may be useful to screen for bladder carcinoma or dysplasia by detecting aneuploidy chromosomes 3, 7, 17 and deletion of the chromosome 9p21 locus in urine specimens. This study aimed to assess the sensitivity, specificity, positive and negative predictive value of FISH in a multi-ethnic population in Asia. MATERIALS AND METHODS Patients with haematuria and/or past history of urothelial cancer on follow-up had their voided urine tested with FISH. Patients then underwent cystoscopy/ ureteroscopy and any lesions seen were biopsied. The histopathological reports of the bladder or ureteroscopic mucosal biopsies were then compared with the FISH test results. RESULTS Two hundred sixty patients were recruited. The sensitivity and specificity of the FISH test was 89.2% and 83.4% respectively. The positive (PPV) and negative predictive values (NPV) were 47.1% and 97.9%. By excluding patients who had positive deletion of chromosome 9, the overall results of the screening test improved: sensitivity 84.6%; specificity 96.4%; PPV 75.9% and NPV 97.9%. CONCLUSIONS UroVysion FISH has a high specificity of detecting urothelial cancer or dysplasia when deletion of chromosome 9 is excluded. Negative UroVysion FISH-tests may allow us to conserve health resources and minimize trauma by deferring cystoscopic or ureteroscopic examination.
Collapse
Affiliation(s)
- Christopher Chee Kong Ho
- Urology Unit, Department of Surgery, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.
| | | | | | | | | |
Collapse
|
5
|
Presence of CSE1L protein in urine of patients with urinary bladder urothelial carcinomas. Int J Biol Markers 2012; 27:e280-4. [PMID: 22653741 DOI: 10.5301/jbm.2012.9310] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/08/2012] [Indexed: 12/23/2022]
Abstract
The chromosome segregation 1-like (CSE1L) protein is highly expressed in most cancers and has been shown to be secreted by tumor cells. We studied the presence of CSE1L in the urine of patients with bladder urothelial carcinomas. The results of our immunohistochemical analysis showed a high expression of CSE1L in bladder cancer specimens, while the normal bladder specimens only showed a very faint staining in some cells. Immunoblotting showed that CSE1L was present in urine of patients with bladder cancer. Urinary CSE1L-positive cases were detected in 95% (57/60) of patients with bladder urothelial carcinomas or the atypical/suspicious cases with urothelial atypia. No CSE1L was detected in urine of healthy controls (p<0.01). Our results suggest that urinary CSE1L deserves further evaluation for the screening of bladder cancer.
Collapse
|